[go: up one dir, main page]

WO1996031525A3 - Inhibiteurs de la farnesyl-proteine transferase - Google Patents

Inhibiteurs de la farnesyl-proteine transferase Download PDF

Info

Publication number
WO1996031525A3
WO1996031525A3 PCT/US1996/003974 US9603974W WO9631525A3 WO 1996031525 A3 WO1996031525 A3 WO 1996031525A3 US 9603974 W US9603974 W US 9603974W WO 9631525 A3 WO9631525 A3 WO 9631525A3
Authority
WO
WIPO (PCT)
Prior art keywords
farnesyl
ca1a2x
inhibitors
thiol
analogs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1996/003974
Other languages
English (en)
Other versions
WO1996031525A2 (fr
Inventor
S Jane Desolms
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Priority to JP53033696A priority Critical patent/JP2002504067A/ja
Priority to AU54285/96A priority patent/AU713698B2/en
Priority to EP96911382A priority patent/EP0837857A4/fr
Publication of WO1996031525A2 publication Critical patent/WO1996031525A2/fr
Publication of WO1996031525A3 publication Critical patent/WO1996031525A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des analogues du motif CA1A2X de la protéine Ras modifiés par farnesylation in vivo. Ces analogues CA1A2X ont un effet inhibiteur sur la farnésyl-protéine transférase et sur la farnesylation de certaines protéines. En outre, ces analogues CA1A2X diffèrent de ceux décrits antérieurement en tant qu'inhibiteurs de farnésyl-protéine transférase par le fait qu'ils ne comportent pas de fraction thiol. L'absence de thiol présente des avantages uniques en termes d'amélioration du comportement pharmacocinétique chez les animaux, de prévention de réactions chimiques dépendantes d'un thiol, telle que l'auto-oxidation rapide et les formations de bisulfure avec des thiols endogènes, et une toxicité systémique réduite. Les composants de cette invention renferment également une fraction amine cyclique à la position A2 du motif. Cette invention recouvre également des compositions chimiothérapeutiques renfermant de tels inhibiteurs de farnesyl transférase et leurs procédés de production.
PCT/US1996/003974 1995-03-29 1996-03-25 Inhibiteurs de la farnesyl-proteine transferase Ceased WO1996031525A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP53033696A JP2002504067A (ja) 1995-03-29 1996-03-25 ファルネシル−タンパク質トランスフェラーゼ阻害剤
AU54285/96A AU713698B2 (en) 1995-03-29 1996-03-25 Inhibitors of farnesyl-protein transferase
EP96911382A EP0837857A4 (fr) 1995-03-29 1996-03-25 Inhibiteurs de la farnesyl-proteine transferase

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US41282895A 1995-03-29 1995-03-29
US41262695A 1995-03-29 1995-03-29
US08/412,626 1996-02-13
US08/412,828 1996-02-13

Publications (2)

Publication Number Publication Date
WO1996031525A2 WO1996031525A2 (fr) 1996-10-10
WO1996031525A3 true WO1996031525A3 (fr) 1996-12-27

Family

ID=27021839

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/003974 Ceased WO1996031525A2 (fr) 1995-03-29 1996-03-25 Inhibiteurs de la farnesyl-proteine transferase

Country Status (1)

Country Link
WO (1) WO1996031525A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703241A (en) * 1995-10-16 1997-12-30 Merck & Co., Inc. Inhibitor of farnesyl-protein transferase
US5932590A (en) * 1996-12-05 1999-08-03 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5238922A (en) * 1991-09-30 1993-08-24 Merck & Co., Inc. Inhibitors of farnesyl protein transferase
US5352705A (en) * 1992-06-26 1994-10-04 Merck & Co., Inc. Inhibitors of farnesyl protein transferase

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5238922A (en) * 1991-09-30 1993-08-24 Merck & Co., Inc. Inhibitors of farnesyl protein transferase
US5352705A (en) * 1992-06-26 1994-10-04 Merck & Co., Inc. Inhibitors of farnesyl protein transferase

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of EP0837857A4 *
THE JOURNAL OF BIOLOGICAL CHEMISTRY, April 1993, Vol. 268, No. 11, GIBBS et al., "Selective Inhibition of Farresyl-Protein Transferase Blocks Ras Process in Vivo", pages 7617-7620. *

Also Published As

Publication number Publication date
WO1996031525A2 (fr) 1996-10-10

Similar Documents

Publication Publication Date Title
WO1996034010A3 (fr) Inhibiteurs de la farnesyle transferase
WO1996010034A3 (fr) Inhibiteurs de la transferase de proteines farnesylees exempts de thiol
WO1997038665A3 (fr) Inhibiteurs de la farnesyl-proteine transferase
RU95109935A (ru) Ингибиторы фарнезил-белковой трансферазы, фармацевтическая композиция, способы лечения
MX9707459A (es) Inhibidores de farnesil-proteina transferasa, composiciones que los contienen y uso de las composiciones.
AU5455394A (en) Inhibitors of farnesyl-protein transferase
IL120266A (en) Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
EP1123120A4 (fr) Formulation d'aerosol medicinal
WO2002057259A3 (fr) Composes de pyrazole utiles en tant qu'inhibiteurs de proteine kinase
EP0282959A3 (fr) 9-Amino-tétrahydro-acridines substitués et composés apparentés, leur procédé de préparation et leur utilisation comme médicaments
WO2000034437A3 (fr) Inhibiteurs de prenyl-proteine transferase
WO1996031525A3 (fr) Inhibiteurs de la farnesyl-proteine transferase
AU1634288A (en) Cyclic anticoagulant peptides
AU1634388A (en) Cyclic anticoagulant peptides
FR2572399B1 (fr) Nouveaux derives de l'adamantanamine, leurs procedes de preparation et medicaments les contenant
WO1996023771A3 (fr) Inhibiteurs de l'agregation plaquettaire
GR3034615T3 (en) Aminophenylalanine derivatives, process for their production, their use and agents containing them as anti-coagulants.
CY2230B1 (en) Stable pharmaceutical compositions containing hybrid alpha-interferon
EP1692952A3 (fr) Assaisonnement de produits alimentaires avec des composés contenant un atome de soufre lié à deux atomes ou groupes spécifiques
GR3020783T3 (en) Substituted, nucleoside derivatives, methods for their preparation and pharmaceutical compositions containing them
WO2000034239A3 (fr) Inhibiteurs de prenyl-proteine transferase
CA2154871A1 (fr) Inhibiteurs de farnesyl-proteine-transferase, agents anti-cancer
Breslin et al. Inhibitors of farnesyl-protein transferase
KR900006282A (ko) 피롤리딘 유도체
TW375525B (en) Inhibitors for morphine-like drug induced emesis containing active components (R)-1-ethyl-4-methyl hexahydro-1H-1,4-diazepine derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AU AZ BB BG BR BY CA CN CZ EE GE HU IS JP KG KR KZ LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK TJ TM TR TT UA US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1996911382

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2216654

Country of ref document: CA

Ref country code: CA

Ref document number: 2216654

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1996911382

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996911382

Country of ref document: EP